Photo of William C. DeWolf,  FACS, MD

William C. DeWolf, FACS, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-8903
Fax: (617) 667-7292


wdewolf@caregroup.harvard.edu

William C. DeWolf, FACS, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Beth Israel Deaconess Medical Center Professor of Surgery, Surgery, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int 2014. PubMed
  • Delto JC, Kacker R, Bubley G, DeWolf WC. Intravesical mitomycin therapy for stage T1 and tis high-grade squamous cell carcinoma of the bladder. Clin Genitourin Cancer 2014; 12:e35-6. PubMed
  • Costa DN, Bloch BN, Yao DF, Sanda MG, Ngo L, Genega EM, Pedrosa I, Dewolf WC, Rofsky NM. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies. Magn Reson Imaging 2013. PubMed
  • Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG, Dewolf WC, Rofsky NM. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol 2012; 22:2201-10. PubMed
  • San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185:471-6. PubMed
  • Dewolf WC. Re: Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. Editorial comment. J Urol 2010; 184:878. PubMed
  • Schopperle WM, Lee JM, Dewolf WC. The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cells. Biochem Biophys Res Commun 2010; 398:372-6. PubMed
  • Lee KS, Zeikus E, DeWolf WC, Rofsky NM, Pedrosa I. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol 2010; 65:185-92. PubMed
  • Olumi AF,Dewolf WC. The hybrid of basic science and clinical training for the urologic oncologit: Necessity or waste? Urol Oncol 2009; 27:205-7. PubMed
  • Pedrosa I,Sun MR,Spencer M,Genega EM,Olumi AF,Dewolf WC,Rofsky NM. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics 2008; 28:985-1003. PubMed
  • Dewolf WC. Re: are doctors examining prostates in university hospital? Eur Urol 2008; 53:1296-7. PubMed
  • Pedrosa I, Chou MT, Ngo L, H Baroni R, Genega EM, Galaburda L, DeWolf WC, Rofsky NM. MR classification of renal masses with pathologic correlation. Eur Radiol 2007; 18:365-75. PubMed
  • Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. Urology 2008; 71:47-51. PubMed
  • Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67:9425-34. PubMed
  • San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006; 175:1341-5; discussion 1345-6. PubMed
  • Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol 2005; 174:1395-8. PubMed
  • Hutchinson LM, Chang EL, Becker CM, Shih MC, Brice M, DeWolf WC, Gaston SM, Zetter BR. Use of thymosin beta15 as a urinary biomarker in human prostate cancer. Prostate 2005; 64:116-27. PubMed
  • Hutchinson LM, Chang EL, Becker CM, Ushiyama N, Behonick D, Shih MC, DeWolf WC, Gaston SM, Zetter BR. Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem 2005; 38:558-71. PubMed
  • San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer 2004; 112:213-8. PubMed
  • Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004; 64:7086-91. PubMed
  • San Francisco IF, Regan MM, Olumi AF, DeWolf WC. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol 2004; 171:1492-9. PubMed
  • George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 2004; 63:327-32. PubMed
  • Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ. Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin Cancer Res 2003; 9:3282-7. PubMed
  • Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol 2002; 169:130-5. PubMed
  • Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C. Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy. J Urol 2002; 168:2249-52. PubMed
  • Gollob JA, Upton MP, DeWolf WC, Atkins MB. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 2001; 58:1058. PubMed
  • Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163:824-7. PubMed
  • Gr. Distinct glycoforms of a tumor specific glycoprotein, gp200, in human testis and testicular tumors. J Urol 1995; 154:275-7. PubMed
  • Morgentaler A, DeWolf WC. A self-expanding prostatic stent for bladder outlet obstruction in high risk patients. J Urol 1993; 150:1636-40. PubMed
  • Schopperle WM, Armant DR, DeWolf WC. Purification of a tumor-specific PNA-binding glycoprotein, gp200, from a human embryonal carcinoma cell line. Arch Biochem Biophys 1992; 298:538-43. PubMed
  • Rukstalis DB, Bubley GJ, Donahue JP, Richie JP, Seidman JG, DeWolf WC. Regional loss of chromosome 6 in two urological malignancies. Cancer Res 1989; 49:5087-90. PubMed
  • Rukstalis DB, DeWolf WC. Molecular biological concepts in the etiology of testicular and other urologic malignancies. Semin Urol 1988; 6:161-70. PubMed
  • DeWolf WC, Carroll PG, Yunis EJ. The genetics of PLT response. I. Methodology for optimal PLT discrimination. J Immunol 1979; 122:860-5. PubMed
  • DeWolf WC, Lange PH, Einarson ME, Yunis EJ. HLA and testicular cancer. Nature 1979; 277:216-7. PubMed
  • Gonzalez R, Dewolf WC. The artificial bladder sphincter AS-721 for the treatment of incontinence in patients with neurogenic bladder. J Urol 1978; 121:71-2. PubMed
Hide